Kallisio Announces Clinical Implementation of Its Patient-Specific Stentra™ System

BALTIMORE--(BUSINESS WIRE)--Kallisio, a company developing patient-specific precision-therapy solutions, announced that it has collaborated with Stanford Health Care to support the clinical implementation of its FDA-cleared Stentra system for use in head and neck cancer radiation therapy.

Stentra is a patient-specific intraoral positioning system designed to support consistent immobilization during external beam radiation therapy. The system produces customized devices based on patient anatomy to assist with tongue and soft tissue positioning during treatment planning and daily radiation delivery.

As part of this collaboration, Stanford Health Care has incorporated Stentra into its clinical workflow for select head and neck cancer cases. The implementation reflects interest in evaluating tools that support reproducible setup and integration within existing radiation oncology processes.

Stentra is designed to be used during CT simulation and throughout the course of radiation therapy. Devices are manufactured using patient-specific digital workflows and are delivered for clinical use within standard treatment timelines. The system is intended to support geometric consistency during treatment while maintaining patient tolerance.

Kallisio’s broader clinical experience with Stentra across multiple institutions has focused on workflow integration, device reproducibility, and patient acceptance within routine radiation oncology operations.

About Kallisio

Kallisio develops patient-specific solutions designed to support precision radiation therapy. The company focuses on scalable, technology-enabled workflows that integrate digital design, manufacturing, and clinical processes to deliver individualized devices for oncology care. Kallisio works with clinical partners to evaluate and implement tools intended to support consistent treatment delivery and reduce variability in radiation therapy. Discover more at kallisio.com.